Singh Biotechnology receives orphan drug designation for STAT3
Food and Drug association, U.S, has granted orphan drug status to SBT-100.
Release Date: 14-Oct-2016
Food and Drug association, U.S, has granted orphan drug status to SBT-100, developed by Singh Biotechnology, a start-up biotech company. STAT3 has novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) B VHH13 single domain antibody (SDAB) SBT100, for the treatment of pancreatic cancer. It can be inhibited either by directly targeting the intracellular protein or indirectly, by targeting the upstream regulators of the STAT3 pathway. Pancreatic cancer is a life threatening disease causing death of almost 95% of all the patients suffering.
Orphan designation is granted by the FDA Office of Orphan Products Development to novel drugs or biologics that treat a rare disease or condition affecting fewer than 200,000 patients in the U.S. The drug also qualifies for financial incentives and tax credits clinical investigation and certain FDA application fee exemption and seven year of market exclusivity on regulatory product approval.
For Orphan Drug Clinical Insight Reports Contact: firstname.lastname@example.org
Need custom market research solution? We can help you with that too.
Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and
service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers
understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas.